Oracle’s $95 Billion Capital Pile-Up: Record Demand, a Lost Deal, and the Price of AI Ambition
Published on 06/23/2026 at 04:03 | Redaktion boerse-global.de
Oracle’s health?care push offers a rare glimpse of steady?state growth in a company otherwise consumed by its own infrastructure spending. The database giant this week announced a partnership with Baystate Health, a Massachusetts?based network of five hospitals and more than 80 physician practices serving roughly 800,000 patients and 13,000 clinicians. The deal will see Oracle’s digital health platform — spanning electronic health records, AI?powered analytics and clinical assistants — replace legacy systems across the network. For Oracle, health?care data contracts provide the kind of recurring, predictable revenue its core cloud business has yet to deliver consistently.
Yet the broader narrative remains dominated by a paradox that has punished the stock for months. Oracle reported a record quarter: $19.2 billion in revenue, up 21% year over year, with cloud revenue surging 47% to $9.9 billion and cloud infrastructure jumping 93%. Remaining performance obligations (RPO), a key forward?looking metric, swelled by $85 billion in the single quarter to a staggering $638 billion. Operating cash flow for the full fiscal year hit $32 billion, a 54% gain. The market’s response? An immediate double?digit sell?off. The stock now trades at €153.56 — roughly 45% below its 52?week high of €280.70 — and on Monday dropped another 4.88% to €152.80.
The tension boils down to cash flow. Oracle posted negative free cash flow of $23.7 billion in fiscal 2026. Cloud and software expenses climbed 56%, outstripping even the torrid growth in cloud revenue, and management is planning capital expenditure of up to $95 billion in the current fiscal year — a figure well above the $50 billion cited in earlier guidance. To fund that, the company is said to be weighing $40 billion in new debt and equity. The result is a balance sheet under strain: a record backlog on one side, massive borrowing on the other.
Should investors sell immediately? Or is it worth buying Oracle?
A separate controversy highlights a structural risk that could cap Oracle’s addressable market. Reports emerged last week that a contract worth more than $3 billion fell through because Oracle refused to obtain FedRAMP certification for its public cloud — the U.S. government’s standardized security framework for handling federal data. Amazon Web Services and Google Cloud already hold that certification. Oracle denied the specifics of the report, but a company manager acknowledged the technical challenge of implementing FedRAMP. Whether or not the deal was real, the incident raises a question: is Oracle’s selective approach to compliance a strategic choice or a limit on its ability to serve regulated sectors such as defense, intelligence and federal health care?
Wall Street analysts, for now, remain bullish. The consensus rating is Buy, with upside of more than 30% from current levels. Management lifted its fiscal 2027 revenue forecast to $90 billion, predicting Oracle Cloud Infrastructure will scale to $144 billion within five years — most of that already booked as RPO. For the first quarter of fiscal 2027, Oracle expects revenue growth of 27% to 29% and cloud growth of 58% to 64%. The multi?cloud database business has been a standout, expanding 531% year over year.
But technical signals suggest deep uncertainty. The stock trades below both its 50?day moving average of €163.47 and its 200?day average of €175.12. The 14?day relative strength index sits at 39.6, indicating bearish momentum. Annualized 30?day volatility is 70.49%. The market is not questioning the growth story; it is questioning the cost of delivering it.
The next milestone for income?focused holders is the July dividend date. The bigger question for all investors is whether Oracle can turn its enormous capital outlay into sustainable positive free cash flow. As long as the cash burn continues — and with $95 billion in planned investment, the burn will only intensify — the stock will remain vulnerable. Scale is not the same as qualification, and winning the AI infrastructure race means more than building out gigawatts and GPU clusters. It means earning the trust of customers in highly regulated industries, where compliance is not optional. Oracle’s selective approach to certification, together with the dilutive financing needed to fund its ambitions, has left the market unconvinced — and at €152.80, the verdict is still out.
Ad
Oracle Stock: New Analysis - 23 June
Fresh Oracle information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
